Ecuador: These 19 Drugs Face Patent Expirations and Generic Entry From 2023 - 2024

Generic name: letermovir
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 02, 2023
Generic Entry Controlled by: Ecuador Patent SP056138
Patent Title: DIHIDROQUINAZOLINAS SUSTITUIDAS

PREVYMIS is a drug marketed by Merck Sharp Dohme. There are three patents protecting this drug.

This drug has eighty-five patent family members in forty-five countries.

See drug price trends for PREVYMIS.

The generic ingredient in PREVYMIS is letermovir. One supplier is listed for this generic product. Additional details are available on the letermovir profile page.

Generic name: siponimod fumaric acid
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 19, 2023
Generic Entry Controlled by: Ecuador Patent SP056148
Patent Title: COMPUESTOS INMUNOSUPRESORES Y COMPOSICIONES

MAYZENT is a drug marketed by Novartis. There are two patents protecting this drug.

This drug has one hundred and forty patent family members in thirty-nine countries.

See drug price trends for MAYZENT.

The generic ingredient in MAYZENT is siponimod fumaric acid. One supplier is listed for this generic product. Additional details are available on the siponimod fumaric acid profile page.

Generic name: metformin hydrochloride; sitagliptin phosphate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: June 24, 2023
Generic Entry Controlled by: Ecuador Patent SP056245
Patent Title: SAL DE ÁCIDO FOSFÓRICO DE UN INHIBIDOR DE LA DIPEPTIDIL PEPTIDASA-IV.

JANUMET is a drug marketed by Merck Sharp Dohme. There are four patents protecting this drug and three Paragraph IV challenges. One tentatively approved generic is ready to enter the market.

This drug has one hundred and thirty-six patent family members in forty-six countries. There has been litigation on patents covering JANUMET

See drug price trends for JANUMET.

The generic ingredient in JANUMET is metformin hydrochloride; sitagliptin phosphate. There are forty-nine drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the metformin hydrochloride; sitagliptin phosphate profile page.

Generic name: metformin hydrochloride; sitagliptin phosphate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: June 24, 2023
Generic Entry Controlled by: Ecuador Patent SP056245
Patent Title: SAL DE ÁCIDO FOSFÓRICO DE UN INHIBIDOR DE LA DIPEPTIDIL PEPTIDASA-IV.

JANUMET XR is a drug marketed by Merck Sharp Dohme. There are three patents protecting this drug and two Paragraph IV challenges. One tentatively approved generic is ready to enter the market.

This drug has one hundred and twenty-seven patent family members in forty-six countries. There has been litigation on patents covering JANUMET XR

See drug price trends for JANUMET XR.

The generic ingredient in JANUMET XR is metformin hydrochloride; sitagliptin phosphate. There are forty-nine drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the metformin hydrochloride; sitagliptin phosphate profile page.

Generic name: sitagliptin phosphate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: June 24, 2023
Generic Entry Controlled by: Ecuador Patent SP056245
Patent Title: SAL DE ÁCIDO FOSFÓRICO DE UN INHIBIDOR DE LA DIPEPTIDIL PEPTIDASA-IV.

JANUVIA is a drug marketed by Merck Sharp Dohme. There are three patents protecting this drug and one Paragraph IV challenge. Twelve tentatively approved generics are ready to enter the market.

This drug has one hundred and twenty-seven patent family members in forty-six countries. There has been litigation on patents covering JANUVIA

See drug price trends for JANUVIA.

The generic ingredient in JANUVIA is sitagliptin phosphate. There are thirty-five drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the sitagliptin phosphate profile page.

Generic name: simvastatin; sitagliptin phosphate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: June 24, 2023
Generic Entry Controlled by: Ecuador Patent SP056245
Patent Title: SAL DE ÁCIDO FOSFÓRICO DE UN INHIBIDOR DE LA DIPEPTIDIL PEPTIDASA-IV.

JUVISYNC is a drug marketed by Merck Sharp Dohme. There are four patents protecting this drug and three Paragraph IV challenges.

This drug has one hundred and twenty-seven patent family members in forty-six countries. There has been litigation on patents covering JUVISYNC

The generic ingredient in JUVISYNC is simvastatin; sitagliptin phosphate. There are forty drug master file entries for this API. Additional details are available on the simvastatin; sitagliptin phosphate profile page.

Generic name: dabigatran etexilate mesylate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: August 29, 2023
Generic Entry Controlled by: Ecuador Patent SP066399
Patent Title: METANOSULFONATO DEL ÉSTER ETÍLICO DEL ÁCIDO 3-[(2-{[4-(HEXILOXICARBONILAMINO-IMINO-METIL)-FENILAMINO]-METIL}-1-METIL-1H-BENCIMIDAZOL-5-CARBONIL)-PIRIDIN-2-IL-AMINO]-PROPIÓNICO Y SU UTILIZACIÓN COMO MEDICAMENTO

PRADAXA is a drug marketed by Boehringer Ingelheim. There are five patents protecting this drug and two Paragraph IV challenges. Ten tentatively approved generics are ready to enter the market.

This drug has two hundred and sixty-eight patent family members in fifty-two countries. There has been litigation on patents covering PRADAXA

See drug price trends for PRADAXA.

The generic ingredient in PRADAXA is dabigatran etexilate mesylate. There are twenty-six drug master file entries for this API. Six suppliers are listed for this generic product. Additional details are available on the dabigatran etexilate mesylate profile page.

Generic name: dabigatran etexilate mesylate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: August 29, 2023
Generic Entry Controlled by: Ecuador Patent SP11006399
Patent Title: METANOSULFONATO DEL ÉSTER ETÍLICO DEL ÁCIDO 3-[(2-{[4-(HEXILOXICARBONILAMINO-IMINO-METIL)-FENILAMINO]-METIL}-1-METIL-1H-BENCIMIDAZOL-5-CARBONIL)-PIRIDIN-2-IL-AMINO]-PROPINÓICO Y SU UTILIZACIÓN COMO MEDICAMENTO

PRADAXA is a drug marketed by Boehringer Ingelheim. There are five patents protecting this drug and two Paragraph IV challenges. Ten tentatively approved generics are ready to enter the market.

This drug has two hundred and sixty-eight patent family members in fifty-two countries. There has been litigation on patents covering PRADAXA

See drug price trends for PRADAXA.

The generic ingredient in PRADAXA is dabigatran etexilate mesylate. There are twenty-six drug master file entries for this API. Six suppliers are listed for this generic product. Additional details are available on the dabigatran etexilate mesylate profile page.

Generic name: rivaroxaban
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: November 27, 2023
Generic Entry Controlled by: Ecuador Patent SP066584
Patent Title: PROCEDIMIENTO PARA LA PRODUCCIÓN DE UNA COMPOSICIÓN FARMACÉUTICA SÓLIDA DE ADMINISTRACIÓN ORAL

XARELTO is a drug marketed by Janssen Pharms. There are five patents protecting this drug and two Paragraph IV challenges. Two tentatively approved generics are ready to enter the market.

This drug has one hundred and fifty-six patent family members in forty-seven countries. There has been litigation on patents covering XARELTO

See drug price trends for XARELTO.

The generic ingredient in XARELTO is rivaroxaban. There are thirty-five drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the rivaroxaban profile page.

Generic name: latanoprostene bunod
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: January 05, 2024
Generic Entry Controlled by: Ecuador Patent SP066684
Patent Title: NITROOXIDERIVADOS DE PROSTAGLANDINAS

VYZULTA is a drug marketed by Bausch And Lomb. There are four patents protecting this drug.

This drug has fifty-three patent family members in thirty-eight countries.

See drug price trends for VYZULTA.

The generic ingredient in VYZULTA is latanoprostene bunod. One supplier is listed for this generic product. Additional details are available on the latanoprostene bunod profile page.

Generic name: empagliflozin; metformin hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: March 16, 2024
Generic Entry Controlled by: Ecuador Patent SP066855
Patent Title: DERIVADOS DE BENCENO SUSTITUIDOS POR GLUCOPIRANOSILO, MEDICAMENTOS QUE CONTIENEN ESOS COMPUESTOS, SU APLICACIÓN Y PROCEDIMIENTO PARA SU PREPARACIÓN

SYNJARDY is a drug marketed by Boehringer Ingelheim. There are seven patents protecting this drug and two Paragraph IV challenges.

This drug has one hundred and ninety-two patent family members in forty-four countries. There has been litigation on patents covering SYNJARDY

See drug price trends for SYNJARDY.

The generic ingredient in SYNJARDY is empagliflozin; metformin hydrochloride. There are twenty-two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the empagliflozin; metformin hydrochloride profile page.

Generic name: empagliflozin; metformin hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: March 16, 2024
Generic Entry Controlled by: Ecuador Patent SP066855
Patent Title: DERIVADOS DE BENCENO SUSTITUIDOS POR GLUCOPIRANOSILO, MEDICAMENTOS QUE CONTIENEN ESOS COMPUESTOS, SU APLICACIÓN Y PROCEDIMIENTO PARA SU PREPARACIÓN

SYNJARDY XR is a drug marketed by Boehringer Ingelheim. There are six patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and sixty-six patent family members in forty countries. There has been litigation on patents covering SYNJARDY XR

See drug price trends for SYNJARDY XR.

The generic ingredient in SYNJARDY XR is empagliflozin; metformin hydrochloride. There are twenty-two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the empagliflozin; metformin hydrochloride profile page.

Generic name: aliskiren hemifumarate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: March 17, 2024
Generic Entry Controlled by: Ecuador Patent SP066807
Patent Title: FORMULACIONES GALÉNICAS DE COMPUESTOS ORGÁNICOS

TEKTURNA is a drug marketed by Noden Pharma. There are three patents protecting this drug and two Paragraph IV challenges.

This drug has forty patent family members in twenty-two countries. There has been litigation on patents covering TEKTURNA

See drug price trends for TEKTURNA.

The generic ingredient in TEKTURNA is aliskiren hemifumarate. There are four drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the aliskiren hemifumarate profile page.

Generic name: etonogestrel
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: March 19, 2024
Generic Entry Controlled by: Ecuador Patent SP066865
Patent Title: DISPOSITIVO DE DISTRIBUCIÓN DE FÁRMACOS VISIBLE POR RAYOS X

IMPLANON is a drug marketed by Organon. There is one patent protecting this drug.

This drug has thirty-two patent family members in twenty-six countries.

The generic ingredient in IMPLANON is etonogestrel. There are five drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the etonogestrel profile page.

Generic name: bazedoxifene acetate; estrogens, conjugated
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: April 07, 2024
Generic Entry Controlled by: Ecuador Patent SP066911
Patent Title: POLIMORFO CRISTALINO DE UN ACETATO DE BAZEDOXIFENO

DUAVEE is a drug marketed by Wyeth Pharms. There are two patents protecting this drug.

This drug has twenty-two patent family members in twenty countries.

See drug price trends for DUAVEE.

The generic ingredient in DUAVEE is bazedoxifene acetate; estrogens, conjugated. There are three drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the bazedoxifene acetate; estrogens, conjugated profile page.

Generic name: dienogest; estradiol valerate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: April 20, 2024
Generic Entry Controlled by: Ecuador Patent SP067000
Patent Title: PREPARADO POLIFÁSICO PARA LA CONTRACEPCIÓN A BASE DE UN ESTRÓGENO NATURAL

NATAZIA is a drug marketed by Bayer Hlthcare. There are two patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.

This drug has ninety patent family members in thirty-nine countries. There has been litigation on patents covering NATAZIA

See drug price trends for NATAZIA.

The generic ingredient in NATAZIA is dienogest; estradiol valerate. There are seven drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the dienogest; estradiol valerate profile page.

Generic name: umeclidinium bromide
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: April 27, 2024
Generic Entry Controlled by: Ecuador Patent SP066940
Patent Title: ANTAGONISTAS DEL RECEPTOR DE ACETILCOLINA MUSCARÍNICO

INCRUSE ELLIPTA is a drug marketed by

This drug has one hundred and seventy-seven patent family members in thirty-nine countries.

See drug price trends for INCRUSE ELLIPTA .

The generic ingredient in INCRUSE ELLIPTA is umeclidinium bromide. There are two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the umeclidinium bromide profile page.

Generic name: dacomitinib
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 06, 2024
Generic Entry Controlled by: Ecuador Patent SP066976
Patent Title: 4-FENILAMINO-QUINAZOLIN-6-IL-AMIDAS

VIZIMPRO is a drug marketed by Pfizer. There are four patents protecting this drug.

This drug has ninety patent family members in forty-seven countries.

See drug price trends for VIZIMPRO.

The generic ingredient in VIZIMPRO is dacomitinib. Two suppliers are listed for this generic product. Additional details are available on the dacomitinib profile page.

Generic name: indacaterol maleate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 13, 2024
Generic Entry Controlled by: Ecuador Patent SP066987
Patent Title: DISPOSITIVO INHALADOR

ARCAPTA NEOHALER is a drug marketed by Novartis. There are two patents protecting this drug.

This drug has eighty-six patent family members in thirty-nine countries. There has been litigation on patents covering ARCAPTA NEOHALER

See drug price trends for ARCAPTA NEOHALER.

The generic ingredient in ARCAPTA NEOHALER is indacaterol maleate. Additional details are available on the indacaterol maleate profile page.

Generic name: glycopyrrolate ; indacaterol maleate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 13, 2024
Generic Entry Controlled by: Ecuador Patent SP066987
Patent Title: DISPOSITIVO INHALADOR

UTIBRON is a drug marketed by Novartis. There are three patents protecting this drug.

This drug has one hundred and forty-eight patent family members in forty countries. There has been litigation on patents covering UTIBRON

See drug price trends for UTIBRON.

The generic ingredient in UTIBRON is glycopyrrolate ; indacaterol maleate. There are seventeen drug master file entries for this API. Additional details are available on the glycopyrrolate ; indacaterol maleate profile page.